Zr-89- Bevacizumab PET Imaging in Primary Breast Cancer

Sietske B. M. Gaykema; Adrienne H. Brouwers; Marjolijn N. Lub-de Hooge; Rick G. Pleijhuis; Hetty Timmer-Bosscha; Linda Pot; Gooitzen M. van Dam; Sibylle B. van der Meulen; Johan R. de Jong; Joost Bart; Jakob de Vries; Liesbeth Jansen; Elisabeth G. E. de Vries; Carolien P. Schroder

doi:10.2967/jnumed.112.117218

Zr-89- Bevacizumab PET Imaging in Primary Breast Cancer

Sietske B. M. Gaykema, Adrienne H. Brouwers, Marjolijn N. Lub-de Hooge, Rick G. Pleijhuis, Hetty Timmer-Bosscha, Linda Pot, Gooitzen M. van Dam, Sibylle B. van der Meulen, Johan R. de Jong, Joost Bart, Jakob de Vries, Liesbeth Jansen, Elisabeth G. E. de Vries, Carolien P. Schroder^*

^*Corresponding author voor dit werk

Onderzoeksoutput: Article › Academic › peer review

138 Citaten (Scopus)

Samenvatting

UNLABELLED: Vascular endothelial growth factor (VEGF)-A is overexpressed in most malignant and premalignant breast lesions. VEGF-A can be visualized noninvasively with PET imaging and using the tracer (89)Zr-labeled bevacizumab. In this clinical feasibility study, we assessed whether VEGF-A in primary breast cancer can be visualized by (89)Zr-bevacizumab PET.

METHODS: Before surgery, breast cancer patients underwent a PET/CT scan of the breasts and axillary regions 4 d after intravenous administration of 37 MBq of (89)Zr-bevacizumab per 5 mg. PET images were compared with standard imaging modalities. (89)Zr-bevacizumab uptake was quantified as the maximum standardized uptake value (SUV max). VEGF-A levels in tumor and normal breast tissues were assessed with enzyme-linked immunosorbent assay. Data are presented as mean ± SD.

RESULTS: Twenty-five of 26 breast tumors (mean size ± SD, 25.1 ± 19.8 mm; range, 4-80 mm) in 23 patients were visualized. SUV max was higher in tumors (1.85 ± 1.22; range, 0.52-5.64) than in normal breasts (0.59 ± 0.37; range, 0.27-1.69; P < 0.001). The only tumor not detected on PET was 10 mm in diameter. Lymph node metastases were present in 10 axillary regions; 4 could be detected with PET (SUV max, 2.66 ± 2.03; range, 1.32-5.68). VEGF-A levels in the 17 assessable tumors were higher than in normal breast tissue in all cases (VEGF-A/mg protein, 184 ± 169 pg vs. 10 ± 21 pg; P = 0.001), whereas (89)Zr-bevacizumab tumor uptake correlated with VEGF-A tumor levels (r = 0.49).

CONCLUSION: VEGF-A in primary breast cancer can be visualized by means of (89)Zr-bevacizumab PET.

Originele taal-2	English
Pagina's (van-tot)	1014-1018
Aantal pagina's	5
Tijdschrift	Journal of Nuclear Medicine
Volume	54
Nummer van het tijdschrift	7
DOI's	https://doi.org/10.2967/jnumed.112.117218
Status	Published - 1-jul.-2013

Toegang tot document

10.2967/jnumed.112.117218

Handle.net

Permanente koppeling

Document onder embargo

89Zr-Bevacizumab PET Imaging in Primary Breast Cancer
Final publisher's version, 662 KB

Citeer dit

Gaykema, S. B. M., Brouwers, A. H., Lub-de Hooge, M. N., Pleijhuis, R. G., Timmer-Bosscha, H., Pot, L., van Dam, G. M., van der Meulen, S. B., de Jong, J. R., Bart, J., de Vries, J., Jansen, L., de Vries, E. G. E., & Schroder, C. P. (2013). Zr-89- Bevacizumab PET Imaging in Primary Breast Cancer. Journal of Nuclear Medicine, 54(7), 1014-1018. https://doi.org/10.2967/jnumed.112.117218

@article{db2da9870a484a7eb28952d91ec2e5a3,

title = "Zr-89- Bevacizumab PET Imaging in Primary Breast Cancer",

abstract = "UNLABELLED: Vascular endothelial growth factor (VEGF)-A is overexpressed in most malignant and premalignant breast lesions. VEGF-A can be visualized noninvasively with PET imaging and using the tracer (89)Zr-labeled bevacizumab. In this clinical feasibility study, we assessed whether VEGF-A in primary breast cancer can be visualized by (89)Zr-bevacizumab PET.METHODS: Before surgery, breast cancer patients underwent a PET/CT scan of the breasts and axillary regions 4 d after intravenous administration of 37 MBq of (89)Zr-bevacizumab per 5 mg. PET images were compared with standard imaging modalities. (89)Zr-bevacizumab uptake was quantified as the maximum standardized uptake value (SUV max). VEGF-A levels in tumor and normal breast tissues were assessed with enzyme-linked immunosorbent assay. Data are presented as mean ± SD.RESULTS: Twenty-five of 26 breast tumors (mean size ± SD, 25.1 ± 19.8 mm; range, 4-80 mm) in 23 patients were visualized. SUV max was higher in tumors (1.85 ± 1.22; range, 0.52-5.64) than in normal breasts (0.59 ± 0.37; range, 0.27-1.69; P < 0.001). The only tumor not detected on PET was 10 mm in diameter. Lymph node metastases were present in 10 axillary regions; 4 could be detected with PET (SUV max, 2.66 ± 2.03; range, 1.32-5.68). VEGF-A levels in the 17 assessable tumors were higher than in normal breast tissue in all cases (VEGF-A/mg protein, 184 ± 169 pg vs. 10 ± 21 pg; P = 0.001), whereas (89)Zr-bevacizumab tumor uptake correlated with VEGF-A tumor levels (r = 0.49).CONCLUSION: VEGF-A in primary breast cancer can be visualized by means of (89)Zr-bevacizumab PET.",

keywords = "breast cancer, VEGF-A, Zr-89-bevacizumab PET, early detection, ENDOTHELIAL GROWTH-FACTOR, RADIATION-EXPOSURE, FDG-PET, VEGF, ANGIOGENESIS, CHEMOTHERAPY, TRIAL",

author = "Gaykema, {Sietske B. M.} and Brouwers, {Adrienne H.} and {Lub-de Hooge}, {Marjolijn N.} and Pleijhuis, {Rick G.} and Hetty Timmer-Bosscha and Linda Pot and {van Dam}, {Gooitzen M.} and {van der Meulen}, {Sibylle B.} and {de Jong}, {Johan R.} and Joost Bart and {de Vries}, Jakob and Liesbeth Jansen and {de Vries}, {Elisabeth G. E.} and Schroder, {Carolien P.}",

year = "2013",

month = jul,

day = "1",

doi = "10.2967/jnumed.112.117218",

language = "English",

volume = "54",

pages = "1014--1018",

journal = "Journal of Nuclear Medicine",

issn = "0161-5505",

publisher = "SOC NUCLEAR MEDICINE INC",

number = "7",

}

TY - JOUR

T1 - Zr-89- Bevacizumab PET Imaging in Primary Breast Cancer

AU - Gaykema, Sietske B. M.

AU - Brouwers, Adrienne H.

AU - Lub-de Hooge, Marjolijn N.

AU - Pleijhuis, Rick G.

AU - Timmer-Bosscha, Hetty

AU - Pot, Linda

AU - van Dam, Gooitzen M.

AU - van der Meulen, Sibylle B.

AU - de Jong, Johan R.

AU - Bart, Joost

AU - de Vries, Jakob

AU - Jansen, Liesbeth

AU - de Vries, Elisabeth G. E.

AU - Schroder, Carolien P.

PY - 2013/7/1

Y1 - 2013/7/1

N2 - UNLABELLED: Vascular endothelial growth factor (VEGF)-A is overexpressed in most malignant and premalignant breast lesions. VEGF-A can be visualized noninvasively with PET imaging and using the tracer (89)Zr-labeled bevacizumab. In this clinical feasibility study, we assessed whether VEGF-A in primary breast cancer can be visualized by (89)Zr-bevacizumab PET.METHODS: Before surgery, breast cancer patients underwent a PET/CT scan of the breasts and axillary regions 4 d after intravenous administration of 37 MBq of (89)Zr-bevacizumab per 5 mg. PET images were compared with standard imaging modalities. (89)Zr-bevacizumab uptake was quantified as the maximum standardized uptake value (SUV max). VEGF-A levels in tumor and normal breast tissues were assessed with enzyme-linked immunosorbent assay. Data are presented as mean ± SD.RESULTS: Twenty-five of 26 breast tumors (mean size ± SD, 25.1 ± 19.8 mm; range, 4-80 mm) in 23 patients were visualized. SUV max was higher in tumors (1.85 ± 1.22; range, 0.52-5.64) than in normal breasts (0.59 ± 0.37; range, 0.27-1.69; P < 0.001). The only tumor not detected on PET was 10 mm in diameter. Lymph node metastases were present in 10 axillary regions; 4 could be detected with PET (SUV max, 2.66 ± 2.03; range, 1.32-5.68). VEGF-A levels in the 17 assessable tumors were higher than in normal breast tissue in all cases (VEGF-A/mg protein, 184 ± 169 pg vs. 10 ± 21 pg; P = 0.001), whereas (89)Zr-bevacizumab tumor uptake correlated with VEGF-A tumor levels (r = 0.49).CONCLUSION: VEGF-A in primary breast cancer can be visualized by means of (89)Zr-bevacizumab PET.

AB - UNLABELLED: Vascular endothelial growth factor (VEGF)-A is overexpressed in most malignant and premalignant breast lesions. VEGF-A can be visualized noninvasively with PET imaging and using the tracer (89)Zr-labeled bevacizumab. In this clinical feasibility study, we assessed whether VEGF-A in primary breast cancer can be visualized by (89)Zr-bevacizumab PET.METHODS: Before surgery, breast cancer patients underwent a PET/CT scan of the breasts and axillary regions 4 d after intravenous administration of 37 MBq of (89)Zr-bevacizumab per 5 mg. PET images were compared with standard imaging modalities. (89)Zr-bevacizumab uptake was quantified as the maximum standardized uptake value (SUV max). VEGF-A levels in tumor and normal breast tissues were assessed with enzyme-linked immunosorbent assay. Data are presented as mean ± SD.RESULTS: Twenty-five of 26 breast tumors (mean size ± SD, 25.1 ± 19.8 mm; range, 4-80 mm) in 23 patients were visualized. SUV max was higher in tumors (1.85 ± 1.22; range, 0.52-5.64) than in normal breasts (0.59 ± 0.37; range, 0.27-1.69; P < 0.001). The only tumor not detected on PET was 10 mm in diameter. Lymph node metastases were present in 10 axillary regions; 4 could be detected with PET (SUV max, 2.66 ± 2.03; range, 1.32-5.68). VEGF-A levels in the 17 assessable tumors were higher than in normal breast tissue in all cases (VEGF-A/mg protein, 184 ± 169 pg vs. 10 ± 21 pg; P = 0.001), whereas (89)Zr-bevacizumab tumor uptake correlated with VEGF-A tumor levels (r = 0.49).CONCLUSION: VEGF-A in primary breast cancer can be visualized by means of (89)Zr-bevacizumab PET.

KW - breast cancer

KW - VEGF-A

KW - Zr-89-bevacizumab PET

KW - early detection

KW - ENDOTHELIAL GROWTH-FACTOR

KW - RADIATION-EXPOSURE

KW - FDG-PET

KW - VEGF

KW - ANGIOGENESIS

KW - CHEMOTHERAPY

KW - TRIAL

U2 - 10.2967/jnumed.112.117218

DO - 10.2967/jnumed.112.117218

M3 - Article

C2 - 23651946

SN - 0161-5505

VL - 54

SP - 1014

EP - 1018

JO - Journal of Nuclear Medicine

JF - Journal of Nuclear Medicine

IS - 7

ER -

Zr-89- Bevacizumab PET Imaging in Primary Breast Cancer

Samenvatting

Toegang tot document

Handle.net

Document onder embargo

Vingerafdruk

Citeer dit